Brookings January 25, 2022
Gregory Ferenstein

In 2020, Oregon voters approved a ballot measure to legalize a psychedelic substance, psilocybin, which is still undergoing clinical trials. Now, the Oregon Health Authority is tasked with the unprecedented challenge of creating its own state-level versions of Food and Drug Administration (FDA) processes, from health provider certifications to accepted use cases.

Traditional sources of evidence, such as experimental academic studies and laboratory clinical trials, are still relatively scarce, so state officials will have to use the very same sources that originally fueled the state’s political movement: the internet.

Because of the illegality of their use, much of the innovation around psychedelic therapy has happened through underground networks of uncertified therapists and the wild west...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Mental Health, Provider, Technology
3 Trends Shaping the Behavioral Health Workforce
Acadia Executes 3 New Acquisitions, Fueling 2024 Growth Strategy
Rady Children’s Embeds Mental Health Into Pediatric Primary Care
InStride Health nabs $30M for virtual pediatric mental health
AI's not ready for depression diagnoses

Share This Article